Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved ...

Oral semaglutide (Rybelsus®) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular ...

Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral ...

Beyond GLP-1 RA prescriptions, chronic kidney disease (CKD) patients require comprehensive care from doctors, dietitians, & ...

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk ...

GLP-1 RAs were associated with positive effects on intracranial hypertension management, including reduced symptoms and treatment burden.

A study reveals rising GLP-1 prescriptions in young women, highlighting low contraception use and potential risks for ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study.

GLP-1s aren't FDA-approved to treat rheumatoid arthritis, but many people notice improvement in their inflammation with the medication — and that's been life-changing for Cassandra Smith.

Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient per year.

Fourteen percent of individuals initiate glucagon-like peptide 1 receptor agonists (GLP-1 RAs) after bariatric surgery, ...